Cite
HARVARD Citation
Awada, G. et al. (2020). Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Journal for immunotherapy of cancer. 8 (2), p. . [Online].